KRAS and colonic neoplasm: Mologni and colleagues found that the β-catenin/TCF inhibitors PKF115-584 and pyrvinium pamoate effectively blocked β-catenin-dependent transcription and synergized with a KRAS inhibitor in colon cancer cells driven by Wnt and KRAS oncogenic signaling.744 However, this combination was ineffective in colon cancer cells harboring BRAF mutations.